Vista Approved Adhd Medications
The U.S. Food and Drug Administration has approved a 30-minute onset of action for the ADHD drug Focalin XR. The new labeling is based on studies that showed Focalin XR improved ADHD symptoms within 30 minutes of administration when compared to a placebo.
More information on "Vista Approved Adhd Medications"
From Our Experts
Blood Pressure Medication to Treat ADHD
Stimulant medications have been the traditional treatment for ADHD for many years. Some people, however, do not tolerate these types of... Read more »
Treating ADHD: When Stimulant Medications Don't Work
Stimulant medications are often used to treat ADHD but it is estimated that between 10 percent and 20 percent of people with ADHD are not... Read more »
Frequently Asked Questions About ADHD Medications
The use of medication to treat symptoms of ADHD brings with it many questions and concerns from both parents and adults with ADHD. Some... Read more »
Myth: ADHD Medication is Not Safe
Most medications prescribed to treat ADHD are stimulant medications and a physician must prescribe all. The majority of medications... Read more »
Methylphenidate for ADHD
Methylphenidate is a central nervous system stimulant medication. It is approved by the U.S. Food and Drug Administration (FDA) to treat... Read more »
From Our Sources
New ADHD drug gets second-round approval from FDA
The U.S. Food and Drug Administration has given second-round approval to NRP104, a new medication for attention-deficit/hyperactivity disorder... Read more »
FDA approves ADHD med Intuniv
The U.S. Food and Drug Administration has approved the extended-release ADHD drug Intuniv. Intuniv will be the first selective alpha-2A receptor... Read more »
New adult ADHD drug up for FDA approval
Drugmaker Shire has applied to the Food and Drug Administration for approval of SPD465 for the treatment of attention-deficit/hyperactivity disorder... Read more »
FDA approves Vyvanse for adult ADHD
The U.S. Food and Drug Administration has approved Vyvanse for the treatment of attention-deficit/hyperactivity disorder in adults. Vyvanse is a new... Read more »
Drugmaker to seek approval for use of NRP104 in adults with AD...
New River Pharmaceuticals has announced that it will file for Food and Drug Administration (FDA) approval for a new medicine to treat adults with... Read more »
Featuring Content From:
By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.
